Dicerna raises $60m in Series C for first human studies
This article was originally published in Scrip
Executive Summary
Dicerna Pharmaceuticals closed a $60 million Series C funding round, which will finance Phase I studies for the Watertown, Massachusetts-based company's first two clinical programs from its RNA interference (RNAi)-based technology platform.